Results 31 to 40 of about 283,903 (204)

Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation

Haematologica, 2012
Background Studies evaluating risk factors for in-hospital venous thromboembolism in children are limited by quality assurance of case definition and/or lack of controlled comparison.
Brian R. Branchford, Peter Mourani, Lalit Bajaj, Marilyn Manco-Johnson, Michael Wang, Neil A. Goldenberg   +5 more
doaj   +1 more source

Prevalence of venous obstructions in (recurrent) venous thromboembolism: a case-control study

Thrombosis Journal, 2020
Background The role of venous obstructions as a risk factor for recurrent venous thromboembolism has never been evaluated. This study aimed to determine whether there is a difference in prevalence of venous obstructions between patients with and without ...
Pascale Notten, Rob H. W. Strijkers, Irwin Toonder, Hugo ten Cate, Arina J. ten Cate-Hoek   +4 more
doaj   +1 more source

THALASSEMIA AND VENOUS THROMBOEMBOLISM

Mediterranean Journal of Hematology and Infectious Diseases, 2011
Although the life expectancy of thalassemia patients has markedly improved over the last few decades, patients still suffer from many complications of this congenital disease. The presence of a high incidence of thromboembolic events, mainly in thalassemia intermedia, has led to the identification of a hypercoagulable state in these patients.
Khaled M. Musallam, Julien Succar, Ali T Taher   +2 more
openaire   +5 more sources

Simple measures can improve care in our hospitals : an audit of venous thromboembolism practice [PDF]

, 2013
: Venous thromboembolism (VTE) is a serious but preventable complication of hospitalisation. Doctors still sometimes fail to adhere to them, thus putting patients at risk and incurring considerable expense for the national health service.
Azzopardi, Stephanie, Lofaro, Thomas, Cordina, John, Busuttil, Sarah   +3 more
core  

Incidence of thromboembolism and thromboprophylaxis in medical patients admitted to specialized hospital in Ethiopia using Padua prediction score

SAGE Open Medicine, 2022
Introduction: Venous thromboembolism is a major cause of mortality and morbidity among hospitalized patients and thromboprophylaxis is one of the key strategies to reduce such events.
Mulugeta Asmamaw, Wubet Hungnaw, Achenef Motbainor, Hanan Muzeyin Kedir, Tamrat Assefa Tadesse   +4 more
doaj   +1 more source

Venous Thromboembolic Disease [PDF]

Journal of the National Comprehensive Cancer Network, 2013
Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication.
Michael B, Streiff, Paula L, Bockenstedt, Spero R, Cataland, Carolyn, Chesney, Charles, Eby, John, Fanikos, Annemarie E, Fogerty, Shuwei, Gao, Samuel Z, Goldhaber, Hani, Hassoun, Paul, Hendrie, Bjorn, Holmstrom, Nicole, Kuderer, Jason T, Lee, Michael M, Millenson, Anne T, Neff, Thomas L, Ortel, Tanya, Siddiqi, Judy L, Smith, Gary C, Yee, Anaadriana, Zakarija, Nicole, McMillian, Maoko, Naganuma   +22 more
openaire   +2 more sources

Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials [PDF]

, 2012
Background - It has been suggested that statins substantially reduce the risk of venous thromboembolic events. We sought to test this hypothesis by performing a meta-analysis of both published and unpublished results from randomised trials of statins.
Jacquet Hervet, Michel, Pieter Kamphuisen, Wikstrand John, Bhala, Neeraj, Haluska, B. A., Sara Biere-Rafi (135090), Kostner, K., Emberson, J, Hegney, D., Pieter Kamphuisen (135078), Bolte, J., McMurray, J.J.V., Delhaas, T., Holliday, J., Wikstrand, J, Glasziou, P. P., Hall, A. S., Samani, N. J., Emberson, J., Carrington, M. J., Blankenberg, S., Reino Maceiras, Maria Victoria, Ling, H. L., Álvarez Álvarez, Belén, Alvarez Castro, Ezequiel, Michele Robertson (135100), Sara Biere-Rafi, Agra Bermejo, Rosa Maria, McMurray, John, Kazem Rahimi (135073), Kamphuisen, P., Frueh, M., Kamphuisen, Pieter, McMurray, J., Schute, F., McMurray John, Biere-Rafi, Sara, Reha-Sleep-Registry, Paradela Dobarro, Beatriz, García Acuña, José María, Janousek, J., Robertson, Michele, Wikstrand, John, Abuassi, Emad, Robertson, M., Kamphuisen, P, Kamke, W., Robertson Michele, Michele Robertson, Zeller, T., Biere-Rafi Sara, Stewart, S., McMurray, J, Peña Gil, Carlos, Rodiño Janeiro, Bruno K, Musameh, M. D., John McMurray, Wang, W. Y. S., Emberson Jonathan, S. Caravita, A. Faini, Neeraj Bhala (135075), John Wikstrand, John McMurray (135109), Keech, A. C., Vera Krane (135094), Jonathan Emberson, Van Geldorp, I., Jonathan Emberson (135084), Rahimi, Kazem, Tonkin, A. M., Elders, J., Rahimi, K, Schroeder, K., S. Salerno, Krane Vera, Krane, V, Vera Krane, Sullivan, D. R., Wikstrand, John,, Bhala, N., Prinzen, F. W., Nelson, C. P., E. Lisi, Krane, V., Biere-Rafi, S., Alt, B., Neeraj Bhala, Skobel, E., Grigorian Shamagian, Lilian, Ball, S. G., G. Parati, Biere-Rafi, S, Kazem Rahimi, ?, ?, Balmforth, A. J., Tomaszewski, M., M. Valentini, John Wikstrand (135105), White, H. D., Carrington, M., Schwaab, B., Rosenthal, E., Raposeiras Roubín, Sergio, Gestal Romani, Santiago, Bhala Neeraj, Cabanas Grandio, Maria Pilar, Emberson, Jonathan, Woehrle, H., Kamphuisen Pieter, Espinoza, D., Tomaske, M., Bhala, N, Hague, W., Rahimi Kazem, G. Bilo, Krane, Vera, P. Agostoni, Rahimi, K., Haluska, B., Krupickova, S., González Juanatey, José Ramón, González Cambeiro, María Cristina, Marwick, T. H., Wikstrand, J., Hiippala, A., Pereira Lopez, Eva Maria, Aguiar Souto, Pablo, Purucker, H. C., Boenner, G., Krüger, S., M. Revera, Simes, R. J., C. Lombardi, Robertson, M   +134 more
core   +2 more sources

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ, Bounameaux, H, A. John Camm, Henri Bounameaux   +3 more
core   +1 more source

Reshaping medical education: Performance of ChatGPT on a PES medical examination

Cardiology Journal
BACKGROUND: We are currently experiencing a third digital revolution driven by artificial intelligence (AI), and the emergence of new chat generative pre-trained transformer (ChatGPT) represents a significant technological advancement with profound ...
Simona Wójcik, Anna Rulkiewicz, Piotr Pruszczyk, Wojciech Lisik, Marcin Poboży, Justyna Domienik-Karłowicz   +5 more
doaj   +1 more source

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding.

PLoS ONE, 2022
This study evaluated effectiveness and safety of apixaban versus warfarin among venous thromboembolism patients at high-risk of bleeding (defined as having at least one of the following bleeding risk factors: ≥75 years; used antiplatelet, NSAIDs, or ...
Alexander T Cohen, Janvi Sah, Amol D Dhamane, Theodore Lee, Lisa Rosenblatt, Patrick Hlavacek, Birol Emir, Allison Keshishian, Huseyin Yuce, Xuemei Luo   +9 more
doaj   +1 more source